Exclusive Summary

• - Macrocyclic GBCA with US registration; originator patents and data exclusivity have long expired, enabling rapid multi-country access and distribution.
• - Globally ~120–140 million MRI exams/year with 35–45% requiring gadolinium contrast, translating to ~42–63 million doses of stable annual demand.
• - Aligned with ACR and ESUR guidance (macrocyclic preferred, safer in renal impairment and repeat imaging), delivering clear clinical value.
• - Competition dominated by Bracco/Guerbet/Bayer macrocyclic brands; linear agents restricted in many markets, leaving price and supply reliability as generic entry points.
• - US registration plus full vial sizes (5/10/15/20 mL) reduce wastage and boost tender cost-effectiveness, with expected 20–40% savings versus originators.